Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-991 in metastatic hormone-sensitive prostate cancer
MOH_2019-12-22_008508Phase 3Not yet recruiting
- Sponsor
- Merck & Co.
- Start
- Dec 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in prostate cancer (PCa) comparing Pembrolizumab + enzalutamide + androgen deprivation therapy with Placebo + enzalutamide + androgen deprivation therapy (2 arms). Planned start Dec 2019; status: not yet recruiting.
02
Drugs
pembrolizumabenzalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on MOH_2019-12-22_008508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-12-22_008508.